Related Experiment Video

Updated: Aug 19, 2026

Establishment and Evaluation of a Risk Prediction Model for Pathological Escalation of Gastric Low-Grade Intraepithelial Neoplasia
03:05

Establishment and Evaluation of a Risk Prediction Model for Pathological Escalation of Gastric Low-Grade Intraepithelial Neoplasia

Published on: February 16, 2024

Gastrointestinal lesions and Helicobacter pylori in patients with myeloproliferative disorders

Ali O Karaoglu1, Gurhan Kadikoylu, Vahit Yukselen

  • 1Gastroenterology Department, Adnan Menderes University Faculty of Medicine, 09100, Aydin, Turkey. yukselenvahit@yahoo.com

Saudi Medical Journal
|February 16, 2005
PubMed
Abstract

Insights

Patients with myeloproliferative disorders (MPD) show significantly higher rates of Helicobacter pylori (H. pylori) infection and gastric lesions. Early H. pylori eradication is recommended for MPD patients to prevent gastrointestinal issues.

Area of Science:

  • Gastroenterology
  • Hematology
  • Infectious Diseases

Background:

  • Myeloproliferative disorders (MPD) are a group of diseases that affect blood cell production.
  • The gastrointestinal manifestations and Helicobacter pylori (H. pylori) status in MPD patients are not well-understood.

Purpose of the Study:

  • To investigate endoscopic findings and H. pylori positivity in patients diagnosed with MPD.
  • To compare these findings with a control group of patients suffering from functional dyspepsia.

Main Methods:

  • A cohort of 30 MPD patients and 93 functional dyspepsia controls underwent physical examination, hemogram, and upper endoscopy.
  • H. pylori status was determined using rapid urease testing and histopathological examination of gastric biopsies.

Main Results:

  • Helicobacter pylori positivity was significantly higher in MPD patients (46.7%) compared to controls (19.4%).
  • The prevalence of gastritis was markedly elevated in the MPD group.
  • Gastrointestinal bleeding occurred in 26.7% of MPD patients, with none reported in the control group.

Conclusions:

  • MPD patients exhibit increased susceptibility to H. pylori infection and a higher frequency of gastric lesions.
  • Regular surveillance for gastrointestinal complications is advised for individuals with MPD.
  • H. pylori eradication is recommended to mitigate potential gastrointestinal problems in MPD patients.

Related Concept Videos

Peptic Ulcer01:27

Peptic Ulcer

Peptic ulcers are erosive lesions of the gastric or duodenal lining, most commonly caused by Helicobacter pylori infection. This Gram-negative, helical bacterium has adapted to survive the stomach’s acidic environment by producing urease, which converts urea into ammonia and carbon dioxide. The ammonia neutralizes gastric acid in the bacterium’s immediate environment, allowing colonization of the gastric mucosa. H. pylori attaches to mucus-secreting epithelial cells, penetrates the mucus...
Gastritis II: Pathophysiology01:26

Gastritis II: Pathophysiology

The pathophysiology of gastritis begins with the colonization of the stomach lining by Helicobacter pylori (H. pylori). This bacterium spreads mainly via the oral-oral route through saliva or shared utensils, and can also be transmitted in overcrowded or unhygienic environments through contaminated water, despite its brief survival outside the body.ColonizationOnce ingested, H. pylori enters the stomach and begins colonization by navigating through the mucus layer lining the stomach wall. It...
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies01:28

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Peptic Ulcer Disease I: Introduction01:30

Peptic Ulcer Disease I: Introduction

Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
Peptic Ulcer Disease II: Pathophysiology01:24

Peptic Ulcer Disease II: Pathophysiology

Peptic ulcer disease develops when protective mechanisms of the gastrointestinal mucosa are overwhelmed by harmful factors, leading to localized erosions in the stomach or proximal duodenum. The main causes are Helicobacter pylori infection and chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs).Helicobacter pylori–Induced InjuryBacterial Adaptation and Colonization:H. pylori is a spiral, Gram-negative bacterium adapted to the acidic stomach. and transmitted through oral-oral or...